HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Atossa Therapeutics (NASDAQ:ATOS) and raises the price target from $4 to $6.
May 13, 2024 | 4:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics' Buy rating is maintained by HC Wainwright & Co., with an increased price target from $4 to $6, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong bullish outlook on the stock, suggesting potential upside. This can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100